Previous 10 | Next 10 |
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the Jefferies Healthcare Conference on June 8, 2022 at 1:00 pm ET in New York City. A live webcast of the presentatio...
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the H.C. Wainwright Global Investment Conference on May 24, 2022 at 4:00 pm ET. A live webcast of the presentation wi...
Savara press release (NASDAQ:SVRA): Q1 GAAP EPS of -$0.05 beats by $0.03. As of March 31, 2022, the Company had cash, cash equivalents, and short-term investments of ~$152 million and debt of ~$25 million. For further details see: Savara GAAP EPS of -$0.05 beats by $0.03
Pivotal Phase 3 IMPALA-2 Trial of Novel Inhaled Biologic, Molgramostim Nebulizer Solution (Molgramostim), in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Remains On-Track for a 20-Month Enrollment, with Top Line Data Expected at the End of 2Q 2024 Company Ends Qu...
Biopharmaceutical company Savara (NASDAQ:SVRA) entered into a $26.5M term loan agreement with Silicon Valley Bank to replace its existing credit facility with the bank. The new agreement has significantly improved economic terms, including a lower interest rate and an initial 48-month in...
Terms Include Reduced Interest Rate of Prime minus .50% and Initial Interest Only Period of 48 Months Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it entered into a term loan agreement o...
Savara press release (NASDAQ:SVRA): Q4 GAAP EPS of -$0.07 in-line. As of December 31, 2021, the Company had cash, cash equivalents and short-term investments of $161.2 million. For further details see: Savara GAAP EPS of -$0.07 in-line
Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Progressing, with Most of the ~50 Clinical Trial Sites Activated Trial Remains On-Track for a 20-Month Enrollment, with Top Line Data Expected...
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at Oppenheimer’s 32nd Annual Healthcare Conference on March 16, 2022 at 3:20 pm ET. A live webcast of the present...
This article focuses on the major influences towards a biotech company's share price, rather than their value or opportunity. These catalysts will be important to consider when timing your entry and exit points. This article will be the last that focuses on evaluating individual h...
News, Short Squeeze, Breakout and More Instantly...
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the pricing of an underwritten offering of 26,246,720 shares of its common stock at a price of $3.81 per share before deducting underwriting discounts and commissions, fo...
2024-06-27 10:15:02 ET Guggenheim analyst issues BUY recommendation for SVRA on June 27, 2024 08:56AM ET. The previous analyst recommendation was Buy. SVRA was trading at $3.84 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analy...
2024-06-27 10:00:08 ET Vamil Divan from Guggenheim issued a price target of $10.00 for SVRA on 2024-06-27 08:56:00. The adjusted price target was set to $10.00. At the time of the announcement, SVRA was trading at $3.84. The overall price target consensus is at $10.50 wi...